Amgen Inc. (AMGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Amgen said first-quarter revenue rose 6% year over year and non-GAAP EPS increased 5%, reinforcing management’s view that 2026 is a "springboard year." The company expects rapidly growing products to offset increased competition in the denosumab franchise, and it highlighted that 16 products delivered double-digit or better sales growth. The update was constructive but largely consistent with ongoing operating momentum rather than a major new catalyst.

Analysis

The key read-through is that Amgen is signaling an inflection from “protection” to “self-funded growth”: the portfolio is now large enough that operating leverage can absorb one franchise roll-off without derailing aggregate EPS. That matters because it reduces the market’s need to underwrite one binary pipeline event; valuation should increasingly hinge on the durability of mid-single-digit top-line growth plus margin discipline rather than on any single asset. For holders, that shifts the debate from “can they replace lost exclusivity?” to “how much of the replacement is already visible in the P&L before the Street marks it in.”

Second-order winners sit downstream of Amgen’s mix shift. If higher-growth products are carrying the year, then the commercial organization is likely optimizing physician access, payer contracting, and manufacturing prioritization around a narrower set of scale assets; that tends to improve inventory efficiency and reduce channel volatility over the next 2-3 quarters. Competitors exposed to the same therapeutic areas but without comparable operating breadth should face a tougher bar, because Amgen can use cash flow to defend share longer and with less earnings sensitivity than smaller peers.

The main risk is that the market extrapolates the current offset too far into 2027-2028. The critical watch item is not next quarter’s revenue print, but whether the growth cohort can sustain enough slope after the denosumab pressure fully annualizes; if growth decelerates faster than consensus, the multiple can compress before the earnings comp is fully visible. A secondary risk is policy or pricing noise around specialty drugs, which would hit a company with a broad U.S. exposure more than names with cleaner international mix.

Contrarian view: this may be less of a “re-rating” setup than a “keep doing what works” setup, which is exactly when investors underpay for quality. The stock can work even without a major upside surprise if the Street has been too focused on patent cliffs and too slow to credit portfolio diversification. The better trade is likely to own the cash-generative compounder into a period of lower headline risk rather than chase an event-driven rerate.

Key Decisions for Investors

• Long AMGN into the next 1-2 earnings cycles; thesis is low-teens downside protection with mid-single-digit EPS compounding if the growth portfolio keeps offsetting franchise pressure. Add on any post-print weakness tied to transitory product mix noise rather than guide-down.
• Pair trade: long AMGN / short a smaller-cap biotech with single-asset concentration and near-term commercial dependency over the next 3-6 months. The spread should widen if investors rotate toward balance-sheet quality and self-funded growth.
• Sell out-of-the-money downside puts on AMGN 1-2 quarters out if implied vol stays elevated; use premium to express the view that the market is overpaying for cliff risk that is increasingly diversified away.
• For more defensive capital, rotate from AMGN peers with higher patent-exposure sensitivity into AMGN; target a 6-12 month hold period where execution, not pipeline optionality, is the main driver.